Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

20 Aug 2019

Abstract excerpt

Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-MEK drug trametinib acquire an exquisite dependency on endoplasmic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Endoplasmic Reticulum Stress and Disease
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31431614
DOI: 10.1038/s41389-019-0158-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancerPMID 31431614Read ↗

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Semantic proximity Read ↗

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read ↗

Identification of drug resistance mechanisms induced in response to KRAS therapeuticsSemantic proximity Read ↗

The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistanceSemantic proximity Read ↗

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.Semantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read ↗

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.